Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.
- Authors
- Cinciripini, Paul M; Tsoh, Janice Y; Wetter, David W; Lam, Cho; de Moor, Carl; Cinciripini, Lynn; Baile, Walter; Anderson, Cheryl; Minna, John D
- Year
- 2005
- Journal
- Experimental and clinical psychopharmacology
- PMID
- 16366758
- DOI
- 10.1037/1064-1297.13.4.282
In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. | Yammine L et al. | — | 2025 | → |
| Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. | Cinciripini PM et al. | — | 2024 | → |
| Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. | Cinciripini PM et al. | — | 2024 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial. | Yammine L et al. | — | 2023 | → |
| Interventions for preventing weight gain after smoking cessation. | Hartmann-Boyce J et al. | — | 2021 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. | Gómez-Coronado N et al. | — | 2018 | → |
| Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial. | Yammine L et al. | — | 2018 | → |
| Why are Antidepressant Drugs Effective Smoking Cessation Aids? | Shoaib M et al. | — | 2018 | → |
| Mirtazapine attenuates the expression of nicotine-induced locomotor sensitization in rats. | Barbosa-Méndez S et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | — | 2016 | → |
| New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline? | Beard E et al. | — | 2016 | → |
| The Role of Depression in the Uptake and Maintenance of Cigarette Smoking. | Audrain-McGovern J et al. | — | 2015 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2014 | → |
| Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. | Ashare RL et al. | — | 2014 | → |
| Reward and affective regulation in depression-prone smokers. | Audrain-McGovern J et al. | — | 2014 | → |
| Insula's functional connectivity with ventromedial prefrontal cortex mediates the impact of trait alexithymia on state tobacco craving. | Sutherland MT et al. | — | 2013 | → |
| Past major depression and smoking cessation outcome: a systematic review and meta-analysis update. | Hitsman B et al. | — | 2013 | → |
| Interventions for preventing weight gain after smoking cessation. | Farley AC et al. | — | 2012 | → |
| Reward expectations lead to smoking uptake among depressed adolescents. | Audrain-McGovern J et al. | — | 2012 | → |
| A multimodal approach to assessing the impact of nicotine dependence, nicotine abstinence, and craving on negative affect in smokers. | Robinson JD et al. | — | 2011 | → |
| Tobacco smoking and mental illness: important considerations. | Feeney S et al. | — | 2011 | → |
| Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. | Buchhalter AR et al. | — | 2008 | → |
| Successful treatment of nicotine withdrawal with duloxetine: a case report. | Perroud N et al. | — | 2008 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2007 | → |
| Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. | Montoya ID et al. | — | 2007 | → |
| The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. | Robinson JD et al. | — | 2007 | → |
| Current and emerging pharmacotherapies for treating tobacco dependence. | Schnoll RA et al. | — | 2006 | → |
| Relationship of DSM-IV-based depressive disorders to smoking cessation and smoking reduction in pregnant smokers. | Blalock JA et al. | — | 2006 | → |